JPM 2025 Healthcare Conference Sparks Debate: Is a Biotech M&A Recovery Underway?

·A biotech investor said that the trading on the morning of August 13 did not indicate the end of the biotech industry's downturn. However, some experts believe that the trading on August 13 was a positive signal, which could usher in a good start for mergers and acquisitions in the biopharmaceuticals industry in 2025 and continue to improve.

On January 13, 2025, the J.P. Morgan Healthcare Conference (hereinafter referred to as "JPM Conference") was held in San Francisco, USA, with several transaction activities announced on the first day drawing attention. Industry insiders at the conference indicated that the increase in M&A activities might imply more active capital movements in the biopharmaceutical field in 2025.

On January 13, GSK (GSK.US) announced that it would acquire the U.S. biotechnology company IDRx. According to the agreement between both parties, GSK will pay a $1 billion upfront payment and potentially an additional $150 million milestone payment contingent upon regulatory approval of the drug. The acquisition includes the lead molecule IDRX-42, a highly selective KIT tyrosine kinase inhibitor intended for first-line and second-line treatment of gastrointestinal stromal tumors.

On the same day, Eli Lilly (LLY.US) announced an acquisition agreement with Scorpion Therapeutics, a precision oncology therapy company. Eli Lilly will acquire Scorpion's PI3Kα inhibitor STX-478, which is currently in Phase 1/2 clinical trials for breast cancer and other advanced solid tumors. Under the agreement, Scorpion’s shareholders are eligible to receive up to $2.5 billion in cash, including an upfront payment and subsequent payments upon achieving regulatory and sales milestones. In addition, as part of the deal, Scorpion will spin off into a new entity, retaining its employees and non-PI3Kα pipeline assets.

The biggest M&A deal of the day came from Johnson & Johnson (JNJ.US). Johnson & Johnson will acquire Intra-Cellular Therapies for $14.6 billion through a combination of cash and debt, demonstrating its commitment to the neuroscience field. This is the largest transaction in the biopharmaceutical industry in nearly two years and the first M&A case exceeding $10 billion in 2024.

Through this acquisition, Johnson & Johnson will gain access to Intra-Cellular Therapies' Caplyta (lumateperone) — a once-daily oral therapy approved for the treatment of adult schizophrenia and depressive episodes associated with bipolar I or II disorder. The acquisition also includes ITI-1284, a compound currently in Phase II research, which is being studied for generalized anxiety disorder (GAD) and Alzheimer's disease-related psychosis.

But according to Endpoints News, a biopharmaceutical industry media outlet, many people are pessimistic about the outlook of the deal. Biotechnology investor Brad Loncar wrote on social media platform X that he believed the trading on the morning of the 13th did not signify the end of the biotechnology sector's downturn. He commented that Johnson & Johnson’s acquisition of Intra-Cellular Therapies was "good," but he anticipated investors would remain concerned about the future of Moderna and Regeneron. Mark McKenna, CEO of Mirador Therapeutics, also stated at the conference, "I wouldn’t say our situation is clear just because of this Johnson & Johnson deal."

But Eric Tokat, Co-President of Centerview Investment Bank, disagrees. He stated, "I believe today's deal is a positive signal, which is expected to give 2025 a good start and continue to improve."

On January 10, 2025, a report released by the financial institution Goldman Sachs was also optimistic, predicting that global M&A activities would significantly accelerate in 2025. It pointed out that multinational pharmaceutical companies such as Roche, Johnson & Johnson, and AbbVie (ABBV.US) generally have healthy and flexible balance sheets for M&A activities around 2025. Due to the strong financial power of major pharmaceutical companies, investors' strong interest in biopharmaceutical innovation, and the industry's thirst for emerging technologies, there may be more M&A deals exceeding $1 billion or even larger in the next two to three years, leading a new round of industry reshuffling.